Today, MAPS has announced that its second Phase 3 trial of MDMA-assisted therapy (MDMA-AT) for PTSD confirms prior positive results. The nonprofit shared few details in its Thursday press release, reproduced below. Data from the 104-participant trial is expected to be published in a peer-reviewed journal later this year. MAPS founder and Executive Director Rick Doblin commented on the 37 year…
